Cargando…
DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading cancers worldwide and has a poor survival, with a 5-year survival rate of only 8.5%. In this study we investigated altered DNA methylation associated with PDAC severity and prognosis. METHODS: Methylome data, generated using 4...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635159/ https://www.ncbi.nlm.nih.gov/pubmed/36329447 http://dx.doi.org/10.1186/s12935-022-02737-1 |
_version_ | 1784824648729362432 |
---|---|
author | Chatterjee, Ankita Bararia, Akash Ganguly, Debopriyo Mondal, Pronoy Kanti Roy, Paromita Banerjee, Sudeep Ghosh, Shibajyoti Gulati, Sumit Ghatak, Supriyo Chattopadhay, Bitan Kumar Basu, Priyadarshi Chatterjee, Aniruddha Sikdar, Nilabja |
author_facet | Chatterjee, Ankita Bararia, Akash Ganguly, Debopriyo Mondal, Pronoy Kanti Roy, Paromita Banerjee, Sudeep Ghosh, Shibajyoti Gulati, Sumit Ghatak, Supriyo Chattopadhay, Bitan Kumar Basu, Priyadarshi Chatterjee, Aniruddha Sikdar, Nilabja |
author_sort | Chatterjee, Ankita |
collection | PubMed |
description | BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading cancers worldwide and has a poor survival, with a 5-year survival rate of only 8.5%. In this study we investigated altered DNA methylation associated with PDAC severity and prognosis. METHODS: Methylome data, generated using 450 K bead array, was compared between paired PDAC and normal samples in the TCGA cohort (n = 9) and our Indian cohort (n = 7). The total Indian Cohort (n = 75) was split into cohort 1 (n = 7), cohort 2 (n = 22), cohort 3 (n = 26) and cohort 4 (n = 20).Validation of differential methylation (6 selected CpG loci) and associated gene expression for differentially methylated genes (10 selected gDMs) were carried out in separate validation cohorts, using MSP, RT-PCR and IHC correlations between methylation and gene expression were observed in TCGA, GTEx cohorts and in validation cohorts. Kaplan–Meier survival analysis was done to study differential prognosis, during 2–5 years of follow-up. RESULTS: We identified 156 DMPs, mapped to 91 genes (gDMs), in PDAC; 68 (43.5%) DMPs were found to be differentially methylated both in TCGA cohort and our cohort, with significant concordance at hypo- and hyper-methylated loci. Enrichments of “regulation of ion transport”, “Interferon alpha/beta signalling”, “morphogenesis and development” and “transcriptional dysregulation” pathways were observed among 91 gDMs. Hyper-methylation of NPY and FAIM2 genes with down-regulated expression in PDAC, were significantly associated with poor prognosis in the Indian patient cohort. CONCLUSIONS: Ethnic variations among populations may determine the altered epigenetic landscape in the PDAC patients of the Indian cohort. Our study identified novel differentially methylated genes (mainly NPY and FAIM2) and also validated the previously identified differentially methylated CpG sites associated with PDAC cancer patient’s survival. Comparative analysis of our data with TCGA and CPTAC cohorts showed that both NPY and FAIM2 hyper-methylation and down-regulations can be novel epigenetically regulated genes in the Indian patient population, statistically significantly associated with poor survival and advanced tumour stages. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02737-1. |
format | Online Article Text |
id | pubmed-9635159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96351592022-11-05 DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort Chatterjee, Ankita Bararia, Akash Ganguly, Debopriyo Mondal, Pronoy Kanti Roy, Paromita Banerjee, Sudeep Ghosh, Shibajyoti Gulati, Sumit Ghatak, Supriyo Chattopadhay, Bitan Kumar Basu, Priyadarshi Chatterjee, Aniruddha Sikdar, Nilabja Cancer Cell Int Research BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading cancers worldwide and has a poor survival, with a 5-year survival rate of only 8.5%. In this study we investigated altered DNA methylation associated with PDAC severity and prognosis. METHODS: Methylome data, generated using 450 K bead array, was compared between paired PDAC and normal samples in the TCGA cohort (n = 9) and our Indian cohort (n = 7). The total Indian Cohort (n = 75) was split into cohort 1 (n = 7), cohort 2 (n = 22), cohort 3 (n = 26) and cohort 4 (n = 20).Validation of differential methylation (6 selected CpG loci) and associated gene expression for differentially methylated genes (10 selected gDMs) were carried out in separate validation cohorts, using MSP, RT-PCR and IHC correlations between methylation and gene expression were observed in TCGA, GTEx cohorts and in validation cohorts. Kaplan–Meier survival analysis was done to study differential prognosis, during 2–5 years of follow-up. RESULTS: We identified 156 DMPs, mapped to 91 genes (gDMs), in PDAC; 68 (43.5%) DMPs were found to be differentially methylated both in TCGA cohort and our cohort, with significant concordance at hypo- and hyper-methylated loci. Enrichments of “regulation of ion transport”, “Interferon alpha/beta signalling”, “morphogenesis and development” and “transcriptional dysregulation” pathways were observed among 91 gDMs. Hyper-methylation of NPY and FAIM2 genes with down-regulated expression in PDAC, were significantly associated with poor prognosis in the Indian patient cohort. CONCLUSIONS: Ethnic variations among populations may determine the altered epigenetic landscape in the PDAC patients of the Indian cohort. Our study identified novel differentially methylated genes (mainly NPY and FAIM2) and also validated the previously identified differentially methylated CpG sites associated with PDAC cancer patient’s survival. Comparative analysis of our data with TCGA and CPTAC cohorts showed that both NPY and FAIM2 hyper-methylation and down-regulations can be novel epigenetically regulated genes in the Indian patient population, statistically significantly associated with poor survival and advanced tumour stages. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02737-1. BioMed Central 2022-11-03 /pmc/articles/PMC9635159/ /pubmed/36329447 http://dx.doi.org/10.1186/s12935-022-02737-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chatterjee, Ankita Bararia, Akash Ganguly, Debopriyo Mondal, Pronoy Kanti Roy, Paromita Banerjee, Sudeep Ghosh, Shibajyoti Gulati, Sumit Ghatak, Supriyo Chattopadhay, Bitan Kumar Basu, Priyadarshi Chatterjee, Aniruddha Sikdar, Nilabja DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort |
title | DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort |
title_full | DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort |
title_fullStr | DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort |
title_full_unstemmed | DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort |
title_short | DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort |
title_sort | dna methylome in pancreatic cancer identified novel promoter hyper-methylation in npy and faim2 genes associated with poor prognosis in indian patient cohort |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635159/ https://www.ncbi.nlm.nih.gov/pubmed/36329447 http://dx.doi.org/10.1186/s12935-022-02737-1 |
work_keys_str_mv | AT chatterjeeankita dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT barariaakash dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT gangulydebopriyo dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT mondalpronoykanti dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT royparomita dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT banerjeesudeep dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT ghoshshibajyoti dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT gulatisumit dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT ghataksupriyo dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT chattopadhaybitankumar dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT basupriyadarshi dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT chatterjeeaniruddha dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort AT sikdarnilabja dnamethylomeinpancreaticcanceridentifiednovelpromoterhypermethylationinnpyandfaim2genesassociatedwithpoorprognosisinindianpatientcohort |